Karpas-620Homo sapiens (Human)Cancer cell line
Also known as: K620, KARPAS620, Karpas620, KARPAS 620, Karpas 620, KARPAS-620
Quick Overview
Human multiple myeloma cell line with B-cell lineage and specific chromosomal translocations.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_1823 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
Age | 77 |
---|---|
Age Category | Adult |
Sex | Female |
Disease Information
Disease | Multiple myeloma |
---|---|
Lineage | Lymphoid |
Subtype | Plasma Cell Myeloma |
OncoTree Code | PCM |
DepMap Information
Source Type | DSMZ |
---|---|
Source ID | ACH-000193_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | TP53 | p.Cys135Tyr (c.404G>A) | Unspecified | - | PubMed=21173094 |
MutationSimple | KRAS | p.Gly12Asp (c.35G>A) | Unspecified | - | PubMed=29786757 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sirota M., Wiita A.P.
Leukemia 34:2754-2765(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Pellat-Deceunynck C.
J. Hematol. Oncol. 11:137.1-137.13(2018).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
Cytometry A 87:285-288(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Pellat-Deceunynck C.
Haematologica 96:574-582(2011).
A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned in close proximity to the 3'IGH enhancer.
Dib A., Glebov O.K., Shou Y.-P., Singer R.H., Kuehl W.M.
DNA Repair 8:330-335(2009).
Characterization of MYC translocations in multiple myeloma cell lines.
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Stewart A.K., Carpten J.D., Bergsagel P.L.
Cancer Cell 12:131-144(2007).
The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Moreau P., Amiot M., Pellat-Deceunynck C.
Haematologica 91:1234-1240(2006).
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Kuehl W.M., Bergsagel P.L.
Blood 97:729-736(2001).
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Drexler H.G., Matsuo Y.
Leuk. Res. 24:681-703(2000).
A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14.
Conneally E., Blaney C., Hayhoe F.G.J., Karpas A.
Br. J. Haematol. 74:70-76(1990).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Multiple myeloma cell lines.";
Jernberg-Wiklund H., Nilsson K.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).